Only 8% of patients attained a partial central nervous system response with neratinib.
The treatment of metastatic brain lesions, related to breast cancer, remains an unmet need. Although surgery, whole-brain radiation, and stereotactic radiation have proven helpful, many patients develop progression of treated metastases or new lesions. In patients with HER2-positive breast cancer, the incidence of brain metastases has increased in large part because systemic treatments, which can control disease outside the central nervous system (CNS), are not able to cross the blood–brain barrier.
The Translational Breast Cancer Research Consortium has conducted a multicenter, open-label, phase II trial to evaluate the effectiveness of the oral, irreversible-binding, tyrosine kinase inhibitor neratinib (240 mg daily) in 40 patients with HE…
Reviewing Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)